1. Pink Sheet
  2. >>Vaccines

Overhyped? White House COVID Coordinator's Claims About New Boosters Go Beyond Data

 
• By Sarah Karlin-Smith

Ashish Jha made promises about the upcoming bivalent COVID-19 boosters that neither he nor the companies are likely going to be able to keep when the rollout begins. 

Ashish Jha, White House Coordinator on Chamber of Commerce event aug 2022
White House COVID-19 Coordinator Ashish Jha spoke at a US Chamber of Commerce event 16 August. • Source: Screenshot from US Chamber of Commerce event

White House COVID-19 Response Coordinator Ashish K. Jha made bold claims about the forthcoming updates to Pfizer Inc./BioNTech SE and Moderna, Inc.’s mRNA COVID vaccines 16 August – statements that contrast to the dearth of clinical data the US Food and Drug Administration is expected to have ahead of a potential fall 2022 authorization and booster campaign.

Some experts said this could have negative consequences, as such communications could influence how people make decisions about the virus

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.